Department of Gastroenterology and Hepatology, University Hospital Heidelberg, INF 410, 69120 Heidelberg, Germany.
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, INF 110, 69120 Heidelberg, Germany.
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101496. doi: 10.1016/j.clinre.2020.07.003. Epub 2021 Mar 16.
Anti-HBc only positive liver grafts may be suitable for HBV-naive recipients insofar as an appropriate infection prophylaxis is performed. Therefore, we investigated the effect of prophylactic regimens on HBV infection prevention and long-term outcome of anti-HBc-positive graft recipients.
This retrospective monocenter study consisted of a cohort of 1912 patients who underwent deceased donor liver transplantation at our transplant center between June 1987 and July 2019. 81 HBV-naïve patients after reception of an anti-HBc-positive liver-graft and consecutive HBV prophylaxis were selected for further examination. HBV infection rate and host- and graft-survival rates were compared to a matched control group consisting of 162 HBV-naïve patients after reception of anti-HBc-negative grafts. Pharmaceutical HBV prophylaxis included: only HBIG, only NUCs, or combined HBIG and NUCs.
Compared to control cases of HBV-naïve anti-HBc-negative graft recipients, no differences in host- and graft-survival rate were determined.13 of 81 anti-HBc-positive graft recipients (16%) developed HBV-infection after liver transplantation. No patient suffered from HBV infection after receiving modern NUCs. Survival analysis showed no statistical differences between patients with and without infection concerning host- and graft-survival.
Especially in times of organ shortage, anti-HBc-positive liver grafts may be useful for liver transplantation in HBV-naïve recipients. Efficient prophylactic regimens can prevent HBV-infection.
只要进行适当的感染预防,仅抗-HBc 阳性的肝移植物可能适合 HBV 初治受者。因此,我们研究了预防方案对 HBV 感染预防和抗-HBc 阳性移植物受者长期结局的影响。
本回顾性单中心研究纳入了 1912 例于 1987 年 6 月至 2019 年 7 月在我院移植中心接受尸体供肝移植的患者。选择 81 例接受抗-HBc 阳性肝移植物且连续接受 HBV 预防的 HBV 初治受者进行进一步检查。与接受抗-HBc 阴性移植物的 162 例 HBV 初治受者的匹配对照组相比,比较了 HBV 感染率和宿主及移植物存活率。药物性 HBV 预防包括:仅 HBIG、仅 NUCs 或 HBIG 和 NUCs 联合。
与 HBV 初治抗-HBc 阴性移植物受者的对照组相比,未确定宿主和移植物存活率的差异。81 例抗-HBc 阳性移植物受者中有 13 例(16%)在肝移植后发生 HBV 感染。接受现代 NUCs 的患者无一例发生 HBV 感染。生存分析显示,感染组与未感染组在宿主和移植物存活率方面无统计学差异。
特别是在器官短缺时期,抗-HBc 阳性肝移植物可用于 HBV 初治受者的肝移植。有效的预防方案可预防 HBV 感染。